Circulating Th22 and Th9 Levels in Patients with Acute Coronary Syndrome

Table 1

Clinical characteristics of patients.

Characteristics	Control; (𝑛=22)	SAP; (𝑛=18)	UAP; (𝑛=23)	AMI; (𝑛=20)
Age (years)	61.4±8.9	61.6±12.3	63.8±10.2	64.3±11.0
Sex (male/female)	15/7	13/5	17/6	15/5
Hypertension, 𝑛 (%)	11 (50.0)	12 (66.6)	15 (65.2)	10 (50.0)
Diabetes, 𝑛 (%)	4 (18.1)	4 (22.2)	5 (21.7)	6 (30.0)
Tobacco, 𝑛 (%)	3 (13.6)	6 (33.3)	4 (17.3)	5 (25.0)
TC (mmol/L)	4.41±0.82	4.09±1.27	4.54±1.41	4.66±1.31
TG (mmol/L)	1.39±0.58	1.53±0.71	1.80±0.76	1.58±0.75
LDL-C (mmol/L)	2.83±0.79	2.74±1.10	2.92±1.20	3.13±1.12^∗
HDL-C (mmol/L)	1.27±0.18	1.02±0.27	1.08±0.36	1.07±0.22
Apo A (mmol/L)	1.36±0.13	1.18±0.18	1.22±0.32	1.15±0.23
Apo B (mmol/L)	0.95±0.29	0.88±0.24	0.97±0.36	0.99±0.27
GLU (mmol/L)	5.12±0.50	5.51±1.19	5.71±1.54	6.44±2.53^∗
Creatinine (µmol/L)	81.00±13.21	98.33±29.30	91.13±16.91	76.25±20.36
CRP (mg/L)	1.27±0.35	2.44±1.67	3.57±2.07^∗	3.87±2.27^∗
LVEF (%)	63.31±5.26	62.55±9.09	59.30±8.37^∗	49.40±10.89^∗
LVEDD (mm)	48.00±1.77	48.05±2.38	48.48±2.85	51.80±3.41^∗
Gensini score	0	29.67±9.96^∗	62.23±29.18^∗	71.15±32.26^∗
Medications, 𝑛 (%)
𝛽-Blockers	3 (13.6)	4 (22.2)	7 (30.4)	4 (20)
ACEI/ARB	2 (9.1)	3 (16.7)	5 (21.7)	4 (20)
CCB	7 (31.8)	8 (44.4)	10 (43.5)	6 (30)
Nitrates	3 (13.6)	6 (33.3)	9 (39.1)	2 (10)
Statins	2 (9.1)	6 (33.3)	7 (30.4)	5 (25)
Aspirin	6 (27.3)	9 (50)	14 (60.9)	10 (50)

The data are given as the mean ± SD or number of patients. SAP: stable angina; UAP: unstable angina; AMI: acute myocardial infarction; TC: total cholesterol; TG: total triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; GLU: fasting glucose; CRP: C-reactive protein; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic dimension; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker.
^∗𝑃<0.05 versus control.